SEC Form 4 · accession 0001209191-19-007343
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqualyn A Fouse
Officer — Chief Executive Officer · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $53.87 | Feb 1, 2019 | A | 350,346 | A | — | Jan 31, 2029 | Common stock | 350,346 | 350,346 | D |
| Performance share unitsF2,F3 | — | Feb 1, 2019 | A | 42,695 | A | — | Feb 1, 2024 | Common stock | 42,695 | 42,695 | D |
Explanation of responses
- F1This option was granted on February 1, 2019. The shares underlying this option vest as to 25% of the shares on February 1, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F2Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- F3The performance share units vest if, during the five-year period beginning on February 1, 2019 and ending on February 1, 2024, the closing price of the issuer's common stock equals or exceeds $120 per share for at least 20 consecutive trading days at any time during such five-year period.